Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study.

@article{Raskin2006DuloxetineFP,
  title={Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study.},
  author={Joel Raskin and Fujun Wang and Yili Lu Pritchett and David John Goldstein},
  journal={Pain medicine},
  year={2006},
  volume={7 5},
  pages={373-85}
}
OBJECTIVE Duloxetine is a relatively balanced and potent reuptake inhibitor of both serotonin and norepinephrine. Because these neurotransmitters play a role in pain inhibition, duloxetine was considered a possible treatment for diabetic peripheral neuropathic pain (DPNP). This study assessed the 6-month safety and tolerability of duloxetine in patients with DPNP; evaluation of efficacy was a secondary objective. DESIGN In this 28-week, open-label study, in the clinical setting, 449 patients… CONTINUE READING